Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females in the developed world. Currently, an important treatment for these patients is the drug AvastinĀ® (bevacizumab), which inhibits tumour blood vessel formation and thus prevents tumour growth.

While molecularly targeted drugs like Avastin offer the ability to manipulate specific molecular interactions, there is the danger that the disease will eventually activate other, previously redundant, cellular pathways, thereby blunting the drug's effectiveness. 

'APO-DECIDE' image


Colorectal cancer (CRC) has among the highest cancer mortality rate worldwide, with over 608,700 deaths per year. Annually, over one million new cases are diagnosed worldwide. APO-DECIDE will develop and validate systems-based biomarkers for apoptosis susceptibility. » read more

'AngioPredict' image


AngioPredict will identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. This will prevent unnecessary treatment, save critical time in patient care and improve quality of life. » read more